Veröffentlichungen der neurologischen klinik

Veröffentlichungen mit Beteiligung der wissenschaftlichen Arbeitsgruppen der
Neurologischen Klinik mit Institut für Klinische Neurobiologie

2004

Originalarbeiten
1.
Bendszus M, Wessig C, Solymosi L, Reiners K, Koltzenburg M. MRI of peripheral nerve degeneration and regeneration: correlation with electrophysiology and histology. Exp Neurol 2004;188:171-177 Bischofs S, Zelenka M, Sommer C. Evaluation of topiramate as an anti-hyperalgesic and neuroprotective agent in the peripheral nervous system. J Peripher Nerv Syst 2004;9:70-78 Buttmann M, Goebeler M, Rieckmann P. Local pain during REBIF injection is not due to acidic pH. J Neurol Neurosurg Psychiatry 2004;75:1078 Buttmann M, Merzyn C, Rieckmann P. IFN-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J. Neuroimmunol. 2004;156:195-203. Chittka A, Arevalo JC, Rodriguez-Guzman M, Perez P, Chao MV, Sendtner M. The p75NTR-interacting protein SC1 inhibits cell cycle progression by transcriptional repression of cyclin E. J Cell Biol 2004;164:985-996 Csoti I, Warmuth-Metz M, Solymosi L, Becker Dagger G, Fornadi F, Naumann M. Differenzierung atypischer Parkinson-Syndrome und ihre Abgrenzung vom idiopathischen Parkinson-Syndrom mit Hilfe der Routine-Magnetresonanztomographie. Nervenarzt 2004;75:128-134 Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M. The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev 2004;18:901-911 Flachenecker P, Bihler I, Weber F, Gottschalk M, Toyka KV, Rieckmann P. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler 2004;10:165-169 Flachenecker P, Rieckmann P. Health outcomes in multiple sclerosis. Curr Opin Neurol 2004;17:257-261 10. * Futh R, Herder C, Forster S, Muller-Scholze S, Kruse N, Rieckmann P, Heinig A, Koenig W, Scherbaum WA, Kolb H, Martin S. Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patients. Cytokine 2004;27:166-172 11. George A, Kleinschnitz C, Zelenka M, Brinkhoff J, Stoll G, Sommer C. Wallerian degeneration after crush or chronic constriction injury of rodent sciatic nerve is associated with a depletion of endoneurial interleukin-10 protein. Exp Neurol 2004;188:187-191 12. George A, Kleinschnitz C, Zelenka M, Brinkhoff J, Stoll G, Sommer C. Wallerian degeneration after crush or chronic constriction injury of rodent sciatic nerve is associated with a depletion of endoneurial interleukin-10 protein. Exp Neurol 2004;188:187-191 13. George A, Buehl A, Sommer C. Wallerian degeneration after crush injury of rat sciatic nerve increases endo- and epineurial tumor necrosis factor-alpha protein. Neurosci Lett 2004;372:215-9. 14. Grohmann K, Rossoll W, Kobsar I, Holtmann B, Jablonka S, Wessig C, Stoltenburg- Didinger G, Fischer U, Hubner C, Martini R, Sendtner M. Characterization of Ighmbp2 in motor neurons and implications for the pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1 (SMARD1). Hum Mol Genet 2004;13:2031-2042 15. Hekman M, Wiese S, Metz R, Albert S, Troppmair J, Nickel J, Sendtner M, Rapp UR. Dynamic changes in C-Raf phosphorylation and 14-3-3 protein binding in response to growth factor stimulation: differential roles of 14-3-3 protein binding sites. J Biol Chem 2004;279:14074-14086 16. Herting B, Wunderlich S, Glockler T, Bendszus M, Mucha D, Reichmann H, Naumann M. Computed tomographically-controlled injection of botulinum toxin into the longus colli muscle in severe anterocollis. Mov Disord 2004;19:588-590 17. *Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, Ahn S, Stolman LP. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 2004;51:274-286 18. Hund M, Rickert S, Kinkelin I, Naumann M, Hamm H. Does wrist nerve block influence the result of botulinum toxin A treatment in palmar hyperhidrosis? J Am Acad Dermatol 2004;50:61-62 19. Jablonka S, Wiese S, Sendtner M. Axonal defects in mouse models of motoneuron 20. Jung S, Gaupp S, Korn T, Kollner G, Hartung HP, Toyka KV. Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization. J Neurosci Res 2004;75:524-535 21. Kahl KG, Kruse N, Rieckmann P, Schmidt MH. Cytokine mRNA expression patterns in the disease course of female adolescents with anorexia nervosa. Psychoneuroendocrinology 2004;29:13-20 22. Kahl KG, Schmidt HH, Jung S, Sherman P, Toyka KV, Zielasek J. Experimental autoimmune encephalomyelitis in mice with a targeted deletion of the inducible nitric oxide synthase gene: increased T-helper 1 response. Neurosci Lett 2004;358:58-62 23. Kallmann BA, Sauer J, Schliesser M, Warmuth-Metz M, Flachenecker P, Becker Dagger G, Rieckmann P, Maurer M. Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-up study. J Neurol 2004;251:30-34 24. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004;30:131-156 25. Kleinschnitz C, Brinkhoff J, Zelenka M, Sommer C, Stoll G. The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol 2004;149:77-83 26. *Kolb-Mäurer A, Weissinger F, Kurzai O, Mäurer M, Wilhelm M, Goebel W. Bacterial infection of human hematopoietic stem cells induces monocytic differentiation. FEMS Immunol Med Microbiol 2004;40:147-153 27. Kroner A, Mäurer M, Loserth S, Kleinschnitz C, Hemmer B, Rosche B, Toyka KV, Rieckmann P. Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in patients with multiple sclerosis. Tissue Antigens 2004;64:70-73 28. Linker RA, Gold R. MBP-induced experimental autoimmune encephalomyelitis in 29. *Löscher WN, Wanschitz J, Reiners K, Quasthoff S. Morvan's syndrome: clinical, laboratory, and in vitro electrophysiological studies. Muscle Nerve 2004;30:157-163 30. Martini R, Toyka KV. Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patients. Lancet Neurol 2004;3:457-465 31. Marziniak M, Mössner R, Benninghoff J, Syagailo YV, Lesch KP, Sommer C. Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine. J Neural Transm 2004;111:603-609 32. Mäurer M, Stoll G, Toyka KV. Multifocal motor neuropathy presenting as chronic progressive proximal leg weakness. Neuromuscul Disord 2004;14:380-382 33. Reif A, Schmitt A, Fritzen S, Chourbaji S, Bartsch C, Urani A, Wycislo M, Mossner R, Sommer C, Gass P, Lesch KP. Differential effect of endothelial nitric oxide synthase (NOS-III) on the regulation of adult neurogenesis and behaviour. Eur J Neurosci 2004;20:885-895 34. Rieckmann P, O'Connor P, Francis GS, Wetherill G, Alteri E. Haematological Effects of Interferon-beta-1a (Rebif((R))) Therapy in Multiple Sclerosis. Drug Saf 2004;27:745-756 35. Rosche B, Cepok S, Stei S, Vogel F, Grummel V, Ziegler A, Kroner A, Mäurer M, Rieckmann P, Sommer N, Hemmer B. The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MS. J. Neuroimmunol. 2004;156:171-177. 36. Runker AE, Kobsar I, Fink T, Loers G, Tilling T, Putthoff P, Wessig C, Martini R, Schachner M. Pathology of a mouse mutation in peripheral myelin protein P0 is characteristic of a severe and early onset form of human Charcot-Marie-Tooth type 1B disorder. J Cell Biol 2004;165:565-573 37. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: Treatment of 10 patients. Neurology 2004; 63:1081-1083. 38. Schäfers M, Marziniak M, Sorkin LS, Yaksh TL, Sommer C. Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol 2004;185:160-168 39. Schoser BG, Kress W, Walter MC, Halliger-Keller B, Lochmuller H, Ricker K. Homozygosity for CCTG mutation in myotonic dystrophy type 2. Brain 2004;127:1868-1877 40. Schoser BG, Schneider-Gold C, Kress W, Goebel HH, Reilich P, Koch MC, Pongratz DE, Toyka KV, Lochmuller H, Ricker K. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve 2004;29:275-281 41. Schramm A, Reiners K, Naumann M. Complex mechanisms of sensory tricks in cervical dystonia. Mov Disord 2004;19:452-458 42. Stefan K, Wycislo M, Classen J. Modulation of associative human motor cortical plasticity by attention. J Neurophysiol 2004;92:66-72 43. Stoll G, Schroeter M, Jander S, Siebert H, Wollrath A, Kleinschnitz C, Bruck W. Lesion-associated expression of transforming growth factor-beta-2 in the rat nervous system: evidence for down-regulating the phagocytic activity of microglia and macrophages. Brain Pathol 2004;14:51-58 44. Stoll G, Wesemeier C, Gold R, Solymosi L, Toyka KV, Bendszus M. In vivo monitoring of macrophage infiltration in experimental autoimmune neuritis by magnetic resonance imaging. J Neuroimmunol 2004;149:142-146 45. Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Muller-Hermelink HK, Marx A. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004;22:1501-1509 46. Ulzheimer JC, Peles E, Levinson SR, Martini R. Altered expression of ion channel isoforms at the node of Ranvier in P0-deficient myelin mutants. Mol Cell Neurosci 2004;25:83-94 47. Visan L, Visan IA, Weishaupt A, Hofstetter HH, Toyka KV, Hunig T, Gold R. Tolerance induction by intrathymic expression of P0. J Immunol 2004;172:1364-1370 48. Volter C, Helms J, Weissbrich B, Rieckmann P, Abele-Horn M. Frequent detection of Mycoplasma pneumoniae in Bell's palsy. Eur Arch Otorhinolaryngol 2004;261:400-404 49. Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 2004;135:49-55 50. Weishaupt A, Kreiss M, Gold R, Herrmann T. Modulation of experimental autoimmune encephalomyelitis by administration of cells expressing antigenic peptide covalently linked to MHC class II. J Neuroimmunol 2004;152:11-19 51. Wessig C, Koltzenburg M, Reiners K, Solymosi L, Bendszus M. Muscle magnetic resonance imaging of denervation and reinnervation: correlation with electrophysiology and histology. Exp Neurol 2004;185:254-261 52. Wiese S, Beck M, Karch C, Sendtner M. Signalling mechanisms for survival of lesioned motoneurons. Acta Neurochir Suppl 2004;89:21-35 53. Wolters A, Classen J, Kunesch E, Grossmann A, Benecke R. Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes. Mov Disord 2004;19:518-528
Übersichtsarbeiten, Buchartikel
1.
Becker G, Dörfler A, Forsting M, Müllges W, Partik B, Prayer D, Wildemann B. Neurodiagnostik in der Intensivmedizin. In: Burchardi, Schuster, Suter. Intensivmedizin. Springer, Stuttgart, 2004: 637-57 Gold R, Ransohoff RM, Sandrock A, Rieckmann P. The blood-brain barrier as target of multiple sclerosis research and therapy. Report of an international scientific meeting, Würzburg, January 23/24, 2004. J Neuroimmunol 2004;152:1-4 Gold R, Müllges W. Guillain- Barre-Syndrom. In: Schwab S, Unterberg U, Werner S, Hacke W. Neuro-Intensiv. Springer, Heidelberg, 2004: in Druck Jost WH, Naumann M. Botulinum toxin in neuro-urological disorders. Mov Disord 2004;19 Supl 8:S142-145 Lindenlaub T, Sommer C. Partial sciatic nerve transection. Methods Mol Med 2004;99:47-53 Müllges W. Cerebral risks in hormone replacement therapy in postmenopausal women. WHI study. Internist 2004; 45:228-30 Müllges W. Does coronary artery bypass grafting cause dementia? Med Welt 2004; 55: in press Müllges W, Baumgartner G. Trepanation bei Media-Infarkt. In: Schneider D. Kontroversen in der Neurologischen Intensivmedizin. Thieme, Stuttgart, 2004 Müllges W, Gold R, Toyka KV. Myasthene Krise. In: Schwab S, Unterberg U, Werner S, Hacke W. Neuro-Intensiv. Springer, Heidelberg, 2004 10. Müllges W. Hypoxisch-ischämische Encephalopathie. In: Schwab S, Unterberg U, Werner S, Hacke W. Neuro-Intensiv. Springer, Heidelberg, 2004Müllges W. Aufgaben und Organisation neurologischer und neurochirurgischer Intensivstationen. In: Schwab S, Unterberg U, Werner S, Hacke W. Neuro-Intensiv. Springer, Heidelberg, 2004. 11. Müllges W. Differenzialdiagnose des prolongierten Komas. In: Eckhart, Forst, Burchardi. Intensivmedizin. Ecomed 2004; II-2.1: 1-14 12. Müllges W. Meningitis. In: Knuth L, Sefrin P. Notfälle nach Leitsymptomen. Deutscher 15. Müllges W, Sommer C. Trigeminusneuralgie. In: Knuth L, Sefrin P. Notfälle nach Leitsymptomen. Deutscher Ärzteverlag 2004Müllges W. Cognitive decline after coronary artery bypass grafting. In: Vellas B, Grundmann P, Feldman H, Fitten LJ, Winblad G, Giacobini E. Research and practice in Alzheimer´s disease and other dementias. Vol 9, Serdi, Paris, 2004: 127-30 16. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004;20:981-990 17. Naumann M, Eberhardt B, Laskawi R, Porta M, Schnider P, Sostak P, Lutze M. Botulinum toxin in rare pain syndromes. J Neurol 2004;251 Suppl 1:I39-40 18. Naumann M, Hamm H. High-dose injection of botulinum toxin to treat focal hyperhidrosis: what's wrong with the concept? J Am Acad Dermatol 2004;50:326-327 19. Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov Disord 20. Sommer C. Patientenkarrieren: Gesichtsschmerz und Neuralgien. Schmerz 2004; 21. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004;361:184-187 22. Sommer C. Serotonin in pain and analgesia: Actions in the periphery. Mol Neurobiol, 23. Sommer C, Schäfers M. Mechanisms of neuropathic pain: the role of cytokines. Drug 24. Stangel M, Gold R. Einsatz von i. v. Immunglobulinen in der Neurologie. Evidenzbasierter Konsens. Nervenarzt 2004;75:801-816
2003

Originalarbeiten
1.
Asan E, Langenhan T, Holtmann B, Bock H, Sendtner M, Carroll P. Ciliary neurotrophic factor in the olfactory bulb of rats and mice. Neuroscience 2003;120:99-112 Bayas A, Gold R. Diagnostische Prinzipien bei Muskelerkrankungen. Fortschr Neurol Psychiatr 2003;71:61-66 Bayas A, Gold R. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment. J Neurol 2003;250 Suppl 4:IV3-8 Bayas A, Kruse N, Moriabadi NF, Weber F, Hummel V, Wohleben G, Gold R, Toyka KV, Rieckmann P. Modulation of cytokine mRNA expression by brain-derived neurotrophic factor and nerve growth factor in human immune cells. Neurosci Lett 2003;335:155-158 Bendszus M, Mullges W, Goldbrunner R, Weigand A, Solymosi L. Hemodynamic effects of decompressive craniotomy in MCA infarction: evaluation with perfusion CT. Eur Radiol 2003;13:1895-1898 Bendszus M, Rieckmann P, Perez J, Koltzenburg M, Reiners K, Solymosi L. Painful vascular compression syndrome of the sciatic nerve caused by gluteal varicosities. Neurology 2003;61:985-987 Bendszus M, Stoll G. Caught in the act: in vivo mapping of macrophage infiltration in nerve injury by magnetic resonance imaging. J Neurosci 2003;23:10892-10896 Bendszus M, Wessig C, Reiners K, Bartsch AJ, Solymosi L, Koltzenberg M. MR imaging in the differential diagnosis of neurogenic foot drop. AJNR Am J Neuroradiol 2003;24:1283-1289 Chan A, Papadimitriou C, Graf W, Toyka KV, Gold R. Effects of polyclonal immunoglobulins and other immunomodulatory agents on microglial phagocytosis of apoptotic inflammatory T-cells. J Neuroimmunol 2003;135:161-165 10. Chan A, Seguin R, Magnus T, Papadimitriou C, Toyka KV, Antel JP, Gold R. Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: termination of CNS autoimmune inflammation and modulation by interferon-beta. Glia 2003;43:231-242 11. Classen J. Focal hand dystonia--a disorder of neuroplasticity? Brain 2003;126:2571- 12. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, Schneider C, Koch MC, Beilman GJ, Harrison AR, Dalton JC, Ranum LP. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003;60:657-664 13. Fallgatter AJ, Neuhauser B, Herrmann MJ, Ehlis AC, Wagener A, Scheuerpflug P, Reiners K, Riederer P. Far field potentials from the brain stem after transcutaneous vagus nerve stimulation. J Neural Transm 2003;110:1437-1443 14. Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis : better outcomes for patients and society? Drugs 2003;63:1525-1533 15. Flachenecker P, Rufer A, Bihler I, Hippel C, Reiners K, Toyka KV, Kesselring J. Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology 2003;61:851-853 16. Flachenecker P, Schneider C, Cursiefen S, Ricker K, Toyka KV, Reiners K. Assessment of cardiovascular autonomic function in myotonic dystrophy type 2 (DM2/PROMM). Neuromuscul Disord 2003;13:289-293 17. Hund M, Rickert S, Kinkelin I, Naumann M, Hamm H. Does wrist nerve block influence the result of botulinum toxin A treatment in palmar hyperhidrosis? J Am Acad Dermatol 2004;50:61-62 18. Jablonka S, Sendtner M. Molecular and cellular basis of spinal muscular atrophy. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:144-149 19. Jann S, Bramerio MA, Beretta S, Koch S, Defanti CA, Toyka KV, Sommer C. Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP. Neurology 2003;61:1607-1610 20. Kahl KG, Kruse N, Rieckmann P, Schmidt MH. Cytokine mRNA expression patterns in the disease course of female adolescents with anorexia nervosa. Psychoneuroendocrinology 2004;29:13-20 21. Kahl KG, Zielasek J, Uttenthal LO, Rodrigo J, Toyka KV, Schmidt HH. Protective role of the cytokine-inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat. J Neurosci Res 2003;73:198-205 22. Kleinschnitz C, Bendszus M, Frank M, Solymosi L, Toyka KV, Stoll G. In vivo monitoring of macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging. J Cereb Blood Flow Metab 2003;23:1356-1361 23. Kobsar I, Berghoff M, Samsam M, Wessig C, Maurer M, Toyka KV, Martini R. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 2003;126:804-813 24. Kolb-Mäurer A, Kammerer U, Maurer M, Gentschev I, Brocker EB, Rieckmann P, Kampgen E. Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes. FEMS Immunol Med Microbiol 2003;35:255-262 25. Kunesch E, Classen J, Bettag M, Kahn T, Ulrich F, Bock WJ, Freund HJ, Seitz RJ. Representational cortical plasticity associated with brain tumours: evidence from laser-induced interstitial thermotherapy. Acta Neurol Scand 2003;108:201-208 26. Kunze K, Müllges W, Röther J, Schwab S, Schneider D, Reuwand A, Guhl M. Pilotstudie zur Qualitätssicherung in der Neurologischen Intensivmedizin. Akt.Neurol 2003; 30: 1-9 27. Leussink V, Reiners K. Elektrophysiologische Diagnostik des Guillain-Barré-Syndroms und verwandter Neuropathien. Klein Neurophysiol 2003; 34:182-196 28. Lindenlaub T, Sommer C. Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol (Berl) 2003;105:593-602 29. Liquori CL, Ikeda Y, Weatherspoon M, Ricker K, Schoser BG, Dalton JC, Day JW, Ranum LP. Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract. Am J Hum Genet 2003;73:849-862 30. Mäurer M, Muller M, Kobsar I, Leonhard C, Martini R, Kiefer R. Origin of pathogenic macrophages and endoneurial fibroblast-like cells in an animal model of inherited neuropathy. Mol Cell Neurosci 2003;23:351-359 31. Merschdorf U, Berg D, Csoti I, Fornadi F, Merz B, Naumann M, Becker G, Supprian T. Psychopathological symptoms of depression in Parkinson's disease compared to major depression. Psychopathology 2003;36:221-225 32. Merz B, Bigalke H, Stoll G, Naumann M. Botulism type B presenting as pure autonomic dysfunction. Clin Auton Res 2003;13:337-338 33. Müllges W, Franke D, Reents W, Babin-Ebell J, Toyka KV. Reduced rate of microembolism by optimized aortic cannula position does not influence early postoperative cognitive performance in CABG patients. Cerebrovasc Dis 2003;15:192-198 34. Naumann M, Lowe NJ, Kumar CR, Hamm H. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003;139:731-736 35. Naumann M, Moore AP. Long-term safety of botulinum toxin type A. Mov Disord 36. Naumann T, Schnell O, Zhi Q, Kirsch M, Schubert KO, Sendtner M, Hofmann HD. Endogenous ciliary neurotrophic factor protects GABAergic, but not cholinergic, septohippocampal neurons following fimbria-fornix transection. Brain Pathol 2003;13:309-321 37. Schäfers M, Geis C, Svensson CI, Luo ZD, Sommer C. Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci 2003;17:791-804 38. Schäfers M, Marziniak M, Sorkin LS, Yaksh TL, Sommer C. Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol 2004;185:160-168 39. Schäfers M, Sorkin LS, Sommer C. Intramuscular injection of tumor necrosis factor- alpha induces muscle hyperalgesia in rats. Pain 2003;104:579-588 40. Schäfers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003;23:2517-2521 41. Schmidt J, Elflein K, Stienekemeier M, Rodriguez-Palmero M, Schneider C, Toyka KV, Gold R, Hunig T. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 2003;140:143-152 42. Schmidt J, Metselaar JM, Gold R. Intravenous liposomal prednisolone downregulates in situ TNF-alpha production by T-cells in experimental autoimmune encephalomyelitis. J Histochem Cytochem 2003;51:1241-1244 43. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003;126:1895-1904 44. Schneider-Gold C, Beck M, Wessig C, George A, Kele H, Reiners K, Toyka KV. Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy. Neurology 2003;60:500-502 45. Schroeter M, Stoll G, Weissert R, Hartung HP, Lassmann H, Jander S. CD8+ phagocyte recruitment in rat experimental autoimmune encephalomyelitis: association with inflammatory tissue destruction. Am J Pathol 2003;163:1517-1524 46. Spindler M, Weilbach F, Beer M, Sandstede J, Kostler H, Strotmann J, Voelker W, Hahn D, Ertl G, Gold R. Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis. J Cardiovasc Pharmacol 2003;42:680-687 47. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study. J Neurol 2003;250:818-821 48. Vogel C, Mössner R, Gerlach M, Heinemann T, Murphy DL, Riederer P, Lesch KP, Sommer C. Absence of thermal hyperalgesia in serotonin transporter-deficient mice. J Neurosci 2003;23:708-715 49. Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 2004;135:49-55 50. Wendland JR, Schmidt KH, Koltzenburg M, Petersen M. No overlap of sensitivity to capsaicin and expression of galanin in rat dorsal root ganglion neurons after axotomy. Exp Brain Res 2003;153:1-6 51. Wessig C, Klein R, Schneider MF, Toyka KV, Naumann M, Sommer C. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003;61:195-198 52. Yaksh TL, Horais KA, Tozier NA, Allen JW, Rathbun M, Rossi SS, Sommer C, Meschter C, Richter PJ, Hildebrand KR. Chronically infused intrathecal morphine in dogs. Anesthesiology 2003;99:174-187
Übersichtsarbeiten, Buchartikel
1.
Gold R, Dalakas MC, Toyka KV. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol 2003;2:22-32 Gold R, Fontana A, Zierz S. Therapy of neurological disorders in systemic vasculitis. Semin Neurol 2003;23:207-214 Heuss D, Schlotter-Weigel B, Sommer C. [Diagnosis and therapy of vasculitic neuropathy. Consensus statement of the German Centers for Neuromuscular Disease]. Fortschr Neurol Psychiatr 2003;71:172-186 Kieseier BC, Gold R, Hartung HP. Mitoxantron zur Therapie der Multiplen Sklerose. Nervenarzt 2003;74:906-910 Müllges W. Diagnostik und Behandlung des Schlaganfalls. In: Langenfeld H, Burrows G.Kochbuch Internistische Intensivmedizin, 2.Aufl., Frankomed, Würzburg 2003: 316-320 Müllges W. Epileptische Anfälle und Status epilepticus. In: ebda., 321-325 Müllges W. Prognose nach Reanimation. In: ebda: 79-83 Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004;20:981-990 10. Reiners K, Gold R. Polyneuropathien. In Paumgartner G, Steinbeck G, Hrsg.: Therapie innerer Krankheiten, 10. Aufl. Berlin: Springer; 2003. S. 1377-1390 11. Reiners K, Mäurer M. Diagnostik bei neuropathischen Schmerzen. In: Sommer C, Hrsg.: Therapie neuropathischer Schmerzsyndrome. Bremen: Uni-Med; 2003. S. 23-34 12. Rieckmann P, Engelhardt B. Building up the blood-brain barrier. Nat Med 2003;9:828- 13. Sommer C. Painful neuropathies. Curr Opin Neurol 2003;16:623-628 14. Toyka KV, Gold R. The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 2003;60:S2-7 15. Wolinsky JS, Toyka KV, Kappos L, Grossberg SE. Interferon-beta antibodies: implications for the treatment of MS. Lancet Neurol 2003;2:528

2002

Originalarbeiten

1.
Bayas A, Hummel V, Kallmann BA, Karch C, Toyka KV, Rieckmann P. Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine 2002;19:55-58 Beck M, Giess R, Magnus T, Puls I, Reiners K, Toyka KV, Naumann M. Progressive sudomotor dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002;73:68-70 Becker G, Berg D, Kruse N, Schroder U, Warmuth-Metz M, Rieckmann P, Naumann M, Reiners K. Evidence for shoulder girdle dystonia in selected patients with cervical disc prolapse. Mov Disord 2002;17:710-716 Beer M, Schneider C, Kostler H, Buchner S, Sandstede J, Toyka KV, Hahn D. Quantitative analysis of energy metabolism in human muscle using SLOOP 31P-MR-spectroscopy. Rofo 2002;174:573-578 Bendszus M, Koltzenburg M. Footdrop after peroneal nerve lesion. J Neurol Neurosurg Psychiatry 2002;72:42 Bendszus M, Koltzenburg M, Wessig C, Solymosi L. Sequential MR imaging of denervated muscle: experimental study. AJNR Am J Neuroradiol 2002;23:1427-1431 Bendszus M, Reents W, Franke D, Mullges W, Babin-Ebell J, Koltzenburg M, Warmuth-Metz M, Solymosi L. Brain damage after coronary artery bypass grafting. Arch Neurol 2002;59:1090-1095 Bendszus M, Reiners K, Perez J, Solymosi L, Koltzenburg M. Peroneal nerve palsy caused by thrombosis of crural veins. Neurology 2002;58:1675-1677 Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005 10. Bommel H, Xie G, Rossoll W, Wiese S, Jablonka S, Boehm T, Sendtner M. Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J Cell Biol 2002;159:563-569 11. Buchwald B, Ahangari R, Toyka KV. Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junction. Neurosci Lett 2002;334:25-28 12. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 2002;51:673-680 13. Flachenecker P, Jung S, Rieckmann P, Toyka KV. sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot study. J 14. Flachenecker P, Kumpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002;8:523-526 15. Giess R, Mäurer M, Linker R, Gold R, Warmuth-Metz M, Toyka KV, Sendtner M, Rieckmann P. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 2002;59:407-409 16. Giess R, Werner E, Beck M, Reiners C, Toyka KV, Naumann m. Impaired salivary gland function reveals autonomic dysfunction in amyotrophic lateral sclerosis. J Neurol 2002;249:1246-1249 17. Grauer O, Wohlleben G, Seubert S, Weishaupt A, Kampgen E, Gold R. Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique. Histochem Cell Biol 2002;117:351-362 18. Grossmann R, Geisen U, Merati G, Mullges W, Schambeck CM, Walter U, Schwender S. Genetic risk factors in young adults with 'cryptogenic' ischemic cerebrovascular disease. Blood Coagul Fibrinolysis 2002;13:583-590 19. Hoitsma E, Marziniak M, Faber CG, Reulen JP, Sommer C, De Baets M, Drent M. Small fibre neuropathy in sarcoidosis. Lancet 2002;359:2085-2086 20. Jablonka S, Holtmann B, Meister G, Bandilla M, Rossoll W, Fischer U, Sendtner M. Gene targeting of Gemin2 in mice reveals a correlation between defects in the biogenesis of U snRNPs and motoneuron cell death. Proc Natl Acad Sci U S A 2002;99:10126-10131 21. Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002;27:671-681 22. Kahl KG, Kruse N, Toyka KV, Rieckmann P. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. J Neurol Sci 2002;200:53-55 23. Kallmann BA, Wagner S, Hummel V, Buttmann M, Bayas A, Tonn JC, Rieckmann P. Characteristic gene expression profile of primary human cerebral endothelial cells. Faseb J 2002;16:589-591 24. Kieseier BC, Tani M, Mahad D, Oka N, Ho T, Woodroofe N, Griffin JW, Toyka KV, Ransohoff RM, Hartung HP. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002;125:823-834 25. Kobsar I, Maurer M, Ott T, Martini R. Macrophage-related demyelination in peripheral nerves of mice deficient in the gap junction protein connexin 32. Neurosci Lett 2002;320:17-20 26. Leussink VI, Zettl UK, Jander S, Pepinsky RB, Lobb RR, Stoll G, Toyka KV, Gold R. Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathol (Berl) 2002;103:131-136 27. Lindenlaub T, Sommer C. Epidermal innervation density after partial sciatic nerve lesion and pain-related behavior in the rat. Acta Neuropathol (Berl) 2002;104:137-143 28. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002;8:620-624 29. Magnus T, Chan A, Linker RA, Toyka KV, Gold R. Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol 2002;61:760- 30. Magnus T, Chan A, Savill J, Toyka KV, Gold R. Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol 2002;130:1- 31. Mäurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N, Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002;54:1-8 32. Mäurer M, Ponath A, Kruse N, Rieckmann P. CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis. J Neuroimmunol 2002;131:213-215 33. Müllges W, Babin-Ebell J, Reents W, Toyka KV. Cognitive performance after coronary artery bypass grafting: a follow-up study. Neurology 2002;59:741-743 34. Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 2002;249:57-63 35. Naumann MK, Hamm H, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002;147:1218-1226 36. Offenhäusser M, Herr AS, Hartkamp J, Wauben M, Magnus T, Grauer O, Seubert S, Weishaupt A, Toyka KV, Gold R, Troppmair J. Truncation of the neuritogenic peptide bP2(60-70) results in the generation of altered peptide ligands with the potential to interfere with T cell activation. J Neuroimmunol 2002;129:97-105 37. Rossoll W, Kroning AK, Ohndorf UM, Steegborn C, Jablonka S, Sendtner M. Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons? Hum Mol Genet 2002;11:93-105 38. Ruprecht K, Stadelmann C, Hummel V, Klein O, Brück W, Rieckmann P. Brain derived neurotrophic factor does not act on adult human cerebral endothelial cells. Neurosci Lett 2002;330:175-178 39. Ruprecht K, Warmuth-Metz M, Waespe W, Gold R. Symptomatic hyperekplexia in a patient with multiple sclerosis. Neurology 2002;58:503-504 40. Ruprecht-Dörfler P, Brechtelsbauer D, Schliesser M, Puls I, Becker G. Prognostic and diagnostic value of global cerebral blood flow volume and cerebral transit time in acute stroke. Ultrasound Med Biol 2002;28:1405-1411 41. Samsam M, Frei R, Marziniak M, Martini R, Sommer C. Impaired sensory function in heterozygous P0 knockout mice is associated with nodal changes in sensory nerves. J Neurosci Res 2002;67:167-173 42. Sand PG, Mori T, Godau C, Stober G, Flachenecker P, Franke P, Nothen MM, Fritze J, Maier W, Lesch KP, Riederer P, Beckmann H, Deckert J. Norepinephrine transporter gene (NET) variants in patients with panic disorder. Neurosci Lett 2002;333:41-44 43. Schäfers M, Geis C, Brors D, Yaksh TL, Sommer C. Anterograde transport of tumor necrosis factor-alpha in the intact and injured rat sciatic nerve. J Neurosci 2002;22:536-545 44. Schäfers M, Schmidt C, Vogel C, Toyka KV, Sommer C. Tumor necrosis factor-alpha (TNF) regulates the expression of ICAM-1 predominantly through TNF receptor 1 after chronic constriction injury of mouse sciatic nerve. Acta Neuropathol (Berl) 2002;104:197-205 45. Schneider C, Gold R, Schäfers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002;25:286-288 46. Schweizer U, Gunnersen J, Karch C, Wiese S, Holtmann B, Takeda K, Akira S, Sendtner M. Conditional gene ablation of Stat3 reveals differential signaling requirements for survival of motoneurons during development and after nerve injury in the adult. J Cell Biol 2002;156:287-297 47. Sommer C. Pharmakologische Behandlung orofazialer Schmerzen. Schmerz 48. Sommer C, Lindenlaub T, Zillikens D, Toyka KV, Naumann M. Selective loss of cholinergic sudomotor fibers causes anhidrosis in Ross syndrome. Ann Neurol 2002;52:247-250 49. Strotmann JM, Spindler M, Weilbach FX, Gold R, Ertl G, Voelker W. Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone. Am J Cardiol 2002;89:1222-1225 50. Weilbach FX, Toyka KV. Does Down's syndrome protect against multiple sclerosis? 51. Weishaupt A, Kuhlmann T, Schonrock LM, Toyka KV, Bruck W, Gold R. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol (Berl) 2002;104:385-390 52. Weiß H, Lauter V, Müllges W, Wagner RF, Toyka KV. Psychotic symptoms and emotional distress in patients suffering from Guillain-Barré syndrome. Eur Neurol 2002; 47: 74-8 53. Wunderlich S, Csoti I, Reiners K, Gunthner-Lengsfeld T, Schneider C, Becker G, Naumann M. Camptocormia in Parkinson's disease mimicked by focal myositis of the paraspinal muscles. Mov Disord 2002;17:598-600
Übersichtsarbeiten, Buchartikel
1.
Mäurer M, Gold R. Animal models of immune-mediated neuropathies. Curr Opin Neurol 2002;15:617-622 Mäurer M, Kobsar I, Berghoff M, Schmid CD, Carenini S, Martini R. Role of immune cells in animal models for inherited neuropathies: facts and visions. J Anat 2002;200:405-414 Mäurer M, Toyka KV, Gold R. Cellular immunity in inflammatory autoimmune neuropathies. Rev Neurol (Paris) 2002;158:S7-15 Mäurer M, Toyka KV, Gold R. Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscul Disord 2002;12:405-414 Müllges W, Stoll G. Hypoxic-ischemic brain injury. Akt Neurol 2002; 29: 431-47 Müllges W. Zerebrovaskuläre Komplikationen nach kardiovaskulären Eingriffen. Neurologie 2002; Thieme, Stuttgart, 2002: 537-4 Naumann M, Hamm H. Treatment of axillary hyperhidrosis. Br J Surg 2002;89:259-261 Rieckmann P, Maurer M. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr Opin Neurol 2002;15:361-370 Rieckmann P, Toyka KV. Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und praktische Umsetzung, Marz 2002. Nervenarzt 2002;73:556-563 10. Stoll G. Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischemia. Rev Neurol (Paris) 2002;158:887-891 11. Stoll G, Jander S, Myers RR. Degeneration and regeneration of the peripheral nervous system: from Augustus Waller's observations to neuroinflammation. J Peripher Nerv Syst 2002;7:13-27 12. Stoll G, Jander S, Schroeter M. Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 2002;513:87-113
2001

Originalarbeiten

1.
Beer M, Sandstede J, Weilbach F, Spindler M, Buchner S, Krug A, Kostler H, Pabst T, Kenn W, Landschutz W, von Kienlin M, Toyka KV, Ertl G, Gold R, Hahn D. Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study. Rofo 2001;173:399-404 Bendszus M, Beck A, Koltzenburg M, Vince GH, Brechtelsbauer D, Littan T, Urbach H, Solymosi L. MRI in isolated sixth nerve palsies. Neuroradiology 2001;43:742-745 Bendszus M, Koltzenburg M. Visualization of denervated muscle by gadolinium-enhanced MRI. Neurology 2001;57:1709-1711 Berg D, Becker G, Naumann M, Reiners K. Morphine in tardive and idiopathic dystonia (short communication). J Neural Transm 2001;108:1035-1041 Berg D, Herrmann MJ, Muller TJ, Strik WK, Aranda D, Koenig T, Naumann M, Fallgatter AJ. Cognitive response control in writer's cramp. Eur J Neurol 2001;8:587-594 Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 2001;50:463-467 Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001;248:684-689 Berg D, Siefker C, Ruprecht-Dörfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001;56:13-17 Buchwald B, Bufler J, Carpo M, Heidenreich F, Pitz R, Dudel J, Nobile-Orazio E, Toyka KV. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 2001;56:67-74 10. Carenini S, Maurer M, Werner A, Blazyca H, Toyka KV, Schmid CD, Raivich G, Martini R. The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in p0. J Cell Biol 2001;152:301-308 11. Chan A, Magnus T, Gold R. Phagocytosis of apoptotic inflammatory cells by microglia and modulation by different cytokines: mechanism for removal of apoptotic cells in the inflamed nervous system. Glia 2001;33:87-95 12. Dazert S, Aletsee C, Brors D, Gravel C, Sendtner M, Ryan A. In vivo adenoviral transduction of the neonatal rat cochlea and middle ear. Hear Res 2001;151:30-40 13. Flachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler 2001;7:327-334 14. Grauer O, Offenhausser M, Schmidt J, Toyka KV, Gold R. Glukokortikosteroid- Therapie bei Optikusneuritis und Multipler Sklerose. Evidenz aus klinischen Studien und praktische Empfehlungen. Nervenarzt 2001;72:577-589 15. Hadden RD, Gregson NA, Gold R, Willison HJ, Hughes RA. Guillain-Barre syndrome serum and anti-Campylobacter antibody do not exacerbate experimental autoimmune neuritis. J Neuroimmunol 2001;119:306-316 16. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath DR, Swan AV, Hughes RA, Toyka KV. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology 2001;56:758-765 17. Hummel V, Kallmann BA, Wagner S, Fuller T, Bayas A, Tonn JC, Benveniste EN, Toyka KV, Rieckmann P. Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules. J Neuropathol Exp Neurol 2001;60:320-327 18. Jablonka S, Bandilla M, Wiese S, Buhler D, Wirth B, Sendtner M, Fischer U. Co- regulation of survival of motor neuron (SMN) protein and its interactor SIP1 during development and in spinal muscular atrophy. Hum Mol Genet 2001;10:497-505 19. Jander S, Lausberg F, Stoll G. Differential recruitment of CD8+ macrophages during Wallerian degeneration in the peripheral and central nervous system. Brain Pathol 2001;11:27-38 20. Jander S, Schroeter M, Peters O, Witte OW, Stoll G. Cortical spreading depression induces proinflammatory cytokine gene expression in the rat brain. J Cereb Blood Flow Metab 2001;21:218-225 21. Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M, Muller W, Sandmann W, Stoll G. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 2001;32:850-854 22. Jander S, Stoll G. Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy. J Neuroimmunol 2001;114:253-258 23. Jordan BW, Dinev D, LeMellay V, Troppmair J, Gotz R, Wixler L, Sendtner M, Ludwig S, Rapp UR. Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death. J Biol Chem 2001;276:39985-39989 24. Jung S, Gaupp S, Hartung HP, Toyka KV. Oral tolerance in experimental autoimmune neuritis (EAN) of the Lewis rat. II. Adjuvant effects and bystander suppression in P2 peptide-induced EAN. J Neuroimmunol 2001;116:21-28 25. Kenn W, Ochs G, Pabst TA, Hahn D. 1H spectroscopy in patients with amyotrophic lateral sclerosis. J Neuroimaging 2001;11:293-297 26. Kiefer G, Rieckmann P. Neuritis nervi optici. Erster Hinweis auf eine Multiple Sklerose? Aktuelle diagnostische und therapeutische Strategien. Ophthalmologe 2001;98:310-318 27. Kieseier BC, Schneider C, Clements JM, Gearing AJ, Gold R, Toyka KV, Hartung HP. Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 2001;124:341-351 28. Korn T, Toyka K, Hartung HP, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain 2001;124:1791-1802 29. Kruse N, Berg D, Francis MJ, Naumann M, Rausch WD, Reiners K, Rieckmann P, Weishaupt A, Becker G. Reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia. Ann Neurol 2001;49:405-408 30. Kruse N, Moriabadi NF, Toyka KV, Rieckmann P. Characterization of early immunological responses in primary cultures of differentially activated human peripheral mononuclear cells. J Immunol Methods 2001;247:131-139 31. Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001;58:91-97 32. Magnus T, Chan A, Grauer O, Toyka KV, Gold R. Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol 2001;167:5004-5010 33. Martini R. The effect of myelinating Schwann cells on axons. Muscle Nerve 34. Mäurer M, Schmid CD, Bootz F, Zielasek J, Toyka KV, Oehen S, Martini R. Bone marrow transfer from wild-type mice reverts the beneficial effect of genetically mediated immune deficiency in myelin mutants. Mol Cell Neurosci 2001;17:1094-1101 35. Moriabadi NF, Niewiesk S, Kruse N, Jung S, Weissbrich B, ter Meulen V, Toyka KV, Rieckmann P. Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 2001;56:938-943 36. Müllges W, Franke D, Reents W, Babin-Ebell J. Brain microembolic counts during extracorporeal circulation depend on aortic cannula position. Ultrasound Med Biol 2001;27:933-936 37. Müllges W, Steinke E, Moldenhauer G, Berens N: Praxis medizinischer Thromboseprophylaxestrümpfe auf konservativen Intensivstationen in Deutschland. Dtsch Med Wschr 2001; 126: 867-71 38. Müllges W, Misoph M, Berg D, Hickethier T, Babin-Ebell J. Einfluß verschiedener Aprotinin-Dosierungen auf die kognitive Leistung nach aortokoronarer Bypass Chirurgie. Z Herz-Thorax-Gefäß Chir 2001;15:29-34 39. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. Bmj 2001;323:596-599 40. Preibisch C, Berg D, Hofmann E, Solymosi L, Naumann M. Cerebral activation patterns in patients with writer's cramp: a functional magnetic resonance imaging study. J Neurol 2001;248:10-17 41. Ruprecht K, Kuhlmann T, Seif F, Hummel V, Kruse N, Bruck W, Rieckmann P. Effects of oncostatin M on human cerebral endothelial cells and expression in inflammatory brain lesions. J Neuropathol Exp Neurol 2001;60:1087-1098 42. Ruprecht K, Rieckmann P, Giess R. Ciguatera: Klinische Bedeutung eines marinen Neurotoxins. Dtsch Med Wochenschr 2001;126:812-814 43. Schäfers M, Brinkhoff J, Neukirchen S, Marziniak M, Sommer C. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 2001;310:113-116 44. Schmidt J, Sturzebecher S, Toyka KV, Gold R. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. J Neurosci Res 2001;65:59-67 45. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 2001;46:79-82 46. Sommer C, Lindenlaub T, Teuteberg P, Schafers M, Hartung T, Toyka KV. Anti-TNF- neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res 2001;913:86-89 47. Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst 2001;6:67-72 48. Stienekemeier M, Falk K, Rotzschke O, Weishaupt A, Schneider C, Toyka KV, Gold R, Strominger JL. Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope. Proc Natl Acad Sci U S A 2001;98:13872-13877 49. Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 2001;58:1076-1079 50. Weishaupt A, Brück W, Hartung T, Toyka KV, Gold R. Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-alpha. Neurosci Lett 2001;306:77-80 51. Weishaupt A, Schönrock LM, Stienekemeier M, Toyka KV, Gold R. Glucocorticosteroids modulate antigen-induced T cell apoptosis in experimental autoimmune neuritis and cause T cell proliferation in situ. Acta Neuropathol (Berl) 2001;102:75-82 52. Wessig C, Buchwald B, Toyka KV, Martini R. Miller Fisher syndrome: immunofluorescence and immunoelectron microscopic localization of IgG at the mouse neuromuscular junction. Acta Neuropathol (Berl) 2001;101:239-244 53. Wunderlich S, Reiners K, Gasser T, Naumann M. Cervical dystonia in monozygotic twins: case report and review of the literature. Mov Disord 2001;16:714-718
Übersichtsarbeiten, Buchartikel

1.
Beck M, Karch C, Wiese S, Sendtner M. Motoneuron cell death and neurotrophic factors: basic models for development of new therapeutic strategies in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2 Suppl 1:S55-68 Becker G, Berg D. Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound. Mov Disord 2001;16:23-32 Becker G, Berg D, Francis M, Naumann M. Evidence for disturbances of copper metabolism in dystonia: from the image towards a new concept. Neurology 2001;57:2290-2294 Becker G, Berg D, Lesch KP, Becker T. Basal limbic system alteration in major depression: a hypothesis supported by transcranial sonography and MRI findings. Int J Neuropsychopharmacol 2001;4:21-31 Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, Becker G. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 2001;79:225-236 Flachenecker P, Toyka KV, Reiners K. Herzrhythmusstörungen beim Guillain-Barre-Syndrom. Eine Ubersicht zur Diagnostik einer seltenen, aber potenziell lebensbedrohlichen Komplikation. Nervenarzt 2001;72:610-617 Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001;117:1-8 Gold R, Müllges W, Toyka KV. Guillain-Barré-Syndrom. In: Eckhart. Kompendium Intensivmedizin. Ecomed, 2001 Koltzenburg M, Scadding J. Neuropathic pain. Curr Opin Neurol 2001;14:641-647 10. Mäurer M, Gold R, Toyka KV, Rieckmann P. Behandlung der schubformigen Multiplen Sklerose mit rekombinanten Interferon-beta-Praparaten. Aspekte zur Pharmakologie und Dosierung. Nervenarzt 2001;72:108-116 11. Müllges W, Steinke E, Moldenhauer G, Berens N. Praxis medizinischer Thromboseprophylaxestrumpfe auf konservativen Intensivstationen in Deutschland. Dtsch Med Wochenschr 2001;126:867-871 12. Müllges W. Diagnostik und Behandlung des Schlaganfalls. In: Langenfeld H, Burrows G: Kochbuch Internistische Intensivmedizin, Frankomed, Würzburg 2001, 294-8 13. Müllges W. Epileptische Anfälle und Status epilepticus. In: ebda., 299-304 14. Müllges W. Hirntod. In: ebda., 327-332 15. Naumann M. Evidence-based medicine: botulinum toxin in focal hyperhidrosis. J 16. Reents W, Müllges W, Franke D, Babin-Ebell J, Elert O. Regional cerebral oxygen 17. saturation assessed by near-infrared spectroscopy during coronary artery bypass grafting with cardiopulmonary bypass and early postoperative cognitive function. In: Lewis BS, Halon DA, Flugelman MY, Hradec J. Advances in coronary artery disease. Monduzzi-Medimont, Bologna,2001:747-53 18. 19. Rieckmann P. Fruhe Multiple-Sklerose-Therapie und ihre gesundheitsokonomischen Auswirkungen. Med Klin (Munich) 2001;96 Suppl 1:17-21 20. Rieckmann P, Smith KJ. Multiple sclerosis: more than inflammation and demyelination. 21. Schneider C, Reiners K, Toyka KV. Myotone Dystrophie (DM/Curschmann-Steinert- Erkrankung) und proximale myotone Myopathie (PROMM/Ricker-Syndrom). Myotone Muskelerkrankungen mit multisystemischen Manifestationen. Nervenarzt 2001;72:618-624 22. Sommer C. Zytokine bei neuropathischen Schmerzen. Anaesthesist 2001;50:416-426

2000

Originalarbeiten
3.
Berg D, Maurer M, Warmuth-Metz M, Rieckmann P, Becker G. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. Arch Neurol 2000;57:1289-1292 Berg D, Preibisch C, Hofmann E, Naumann M. Cerebral activation pattern in primary writing tremor. J Neurol Neurosurg Psychiatry 2000;69:780-786 Berg D, Supprian T, Thomae J, Warmuth-Metz M, Horowski A, Zeiler B, Magnus T, Rieckmann P, Becker G. Lesion pattern in patients with multiple sclerosis and depression. Mult Scler 2000;6:156-162 Berg D, Weishaupt A, Francis MJ, Miura N, Yang XL, Goodyer ID, Naumann M, Koltzenburg M, Reiners K, Becker G. Changes of copper-transporting proteins and ceruloplasmin in the lentiform nuclei in primary adult-onset dystonia. Ann Neurol 2000;47:827-830 Cursiefen S, Flachenecker P, Toyka KV, Rieckmann P. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis. Eur Neurol 2000;43:186-187 Dörfler P, Puls I, Schliesser M, Maurer M, Becker G. Measurement of cerebral blood flow volume by extracranial sonography. J Cereb Blood Flow Metab 2000;20:269-271 Flachenecker P, Kumpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002;8:523-526 10. Flachenecker P, Lem K, Mullges W, Reiners K. Detection of serious bradyarrhythmias in Guillain-Barre syndrome: sensitivity and specificity of the 24-hour heart rate power spectrum. Clin Auton Res 2000;10:185-191 12. George A, Marziniak M, Schafers M, Toyka KV, Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 2000;88:267-275 13. Giess R, Beck M, Goetz R, Nitsch RM, Toyka KV, Sendtner M. Potential role of LIF as a modifier gene in the pathogenesis of amyotrophic lateral sclerosis. Neurology 2000;54:1003-1005 14. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka KV. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000;69:121-123 16. Götz R, Karch C, Digby MR, Troppmair J, Rapp UR, Sendtner M. The neuronal apoptosis inhibitory protein suppresses neuronal differentiation and apoptosis in PC12 cells. Hum Mol Genet 2000;9:2479-2489 17. Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W, Kiefer R, Muller- Hermelink HK, Marx A. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 2000;96:3872-3879 19. Jablonka S, Schrank B, Kralewski M, Rossoll W, Sendtner M. Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. Hum Mol Genet 2000;9:341-346 20. Kallmann BA, Hummel V, Lindenlaub T, Ruprecht K, Toyka KV, Rieckmann P. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 2000;123 ( Pt 4):687-697 21. Keberle M, Jenett M, Kenn W, Reiners K, Peter M, Haerten R, Hahn D. Technical advances in ultrasound and MR imaging of carpal tunnel syndrome. Eur Radiol 2000;10:1043-1050 22. Kieseier BC, Krivacic K, Jung S, Pischel H, Toyka KV, Ransohoff RM, Hartung HP. Sequential expression of chemokines in experimental autoimmune neuritis. J Neuroimmunol 2000;110:121-129 23. Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 2000;143:824-827 24. Kress W, Mueller-Myhsok B, Ricker K, Schneider C, Koch MC, Toyka KV, Mueller CR, Grimm T. Proof of genetic heterogeneity in the proximal myotonic myopathy syndrome (PROMM) and its relationship to myotonic dystrophy type 2 (DM2). Neuromuscul Disord 2000;10:478-480 25. Kruse N, Greif M, Moriabadi NF, Marx L, Toyka KV, Rieckmann P. Variations in cytokine mRNA expression during normal human pregnancy. Clin Exp Immunol 2000;119:317-322 26. Lindenlaub T, Sommer C. Partial sciatic nerve transection as a model of neuropathic pain: a qualitative and quantitative neuropathological study. Pain 2000;89:97-106 27. Lindenlaub T, Teuteberg P, Hartung T, Sommer C. Effects of neutralizing antibodies to TNF-alpha on pain-related behavior and nerve regeneration in mice with chronic constriction injury. Brain Res 2000;866:15-22 28. Martini R. Animal models for inherited peripheral neuropathies: chances to find treatment strategies? J Neurosci Res 2000;61:244-250 29. Martini R, Berciano J, Van Broeckhoven C. 5th Workshop of the European CMT Consortium, 69th ENMC International Workshop: therapeutic approaches in CMT neuropathies and related disorders 23-25 April 1999, Soestduinen, The Netherlands. Neuromuscul Disord 2000;10:69-74 30. Mäurer M, Becker G, Wagner R, Woydt M, Hofmann E, Puls I, Lindner A, Krone A. Early postoperative transcranial sonography (TCS), CT, and MRI after resection of high grade glioma: evaluation of residual tumour and its influence on prognosis. Acta Neurochir (Wien) 2000;142:1089-1097 31. Mäurer M, Kruse N, Giess R, Toyka KV, Rieckmann P. Genetic variation at position - 1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis. J Neuroimmunol 2000;104:98-100 32. McLellan AD, Terbeck G, Mengling T, Starling GC, Kiener PA, Gold R, Brocker EB, Leverkus M, Kampgen E. Differential susceptibility to CD95 (Apo-1/Fas) and MHC class II-induced apoptosis during murine dendritic cell development. Cell Death Differ 2000;7:933-938 33. Metzger F, Kulik A, Sendtner M, Ballanyi K. Contribution of Ca(2+)-permeable AMPA/KA receptors to glutamate-induced Ca(2+) rise in embryonic lumbar motoneurons in situ. J Neurophysiol 2000;83:50-59 34. Müllges W, Berg D, Schmidtke A, Weinacker B, Toyka KV. Early natural course of transient encephalopathy after coronary artery bypass grafting. Crit Care Med 2000;28:1808-1811 35. Naumann M, Magyar-Lehmann S, Reiners K, Erbguth F, Leenders KL. Sensory tricks in cervical dystonia: perceptual dysbalance of parietal cortex modulates frontal motor programming. Ann Neurol 2000;47:322-328 36. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:201-206 37. Puls I, Berg D, Maurer M, Schliesser M, Hetzel G, Becker G. Transcranial sonography of the brain parenchyma: comparison of B-mode imaging and tissue harmonic imaging. Ultrasound Med Biol 2000;26:189-194 38. Ricker K. The expanding clinical and genetic spectrum of the myotonic dystrophies. 39. Schmid CD, Stienekemeier M, Oehen S, Bootz F, Zielasek J, Gold R, Toyka KV, Schachner M, Martini R. Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J Neurosci 2000;20:729-735 40. Schmidt J, Gold R, Schonrock L, Zettl UK, Hartung HP, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000;123 ( Pt 7):1431-1441 41. Schneider C, Grimm T, Kress W, Sommer C, Muller CR. Hyperparathyroidism in a patient with proximal myotonic myopathy (PROMM). Neuromuscul Disord 2000;10:481-483 42. Schneider C, Matsumoto Y, Kohyama K, Toyka KV, Hartung HP, Gold R. Experimental autoimmune myositis in the lewis rat: lack of spontaneous T-cell apoptosis and therapeutic response to glucocorticosteroid application. J Neuroimmunol 2000;107:83-87 43. Schneider C, Ziegler A, Ricker K, Grimm T, Kress W, Reimers CD, Meinck H, Reiners K, Toyka KV. Proximal myotonic myopathy: evidence for anticipation in families with linkage to chromosome 3q. Neurology 2000;55:383-388 44. Schneider C, Reiners K. Elektrophysiologische Diagnostik neuromuskulärer Übertragungsstörungen. Klin Neurophysiol 2000; 21:122-135 45. Sendtner M, Pei G, Beck M, Schweizer U, Wiese S. Developmental motoneuron cell death and neurotrophic factors. Cell Tissue Res 2000;301:71-84 46. Stienekemeier M, Hofmann K, Gold R, Herrmann T. A polymorphism of the rat T-cell receptor beta-chain variable gene 13 (BV13S1) correlates with the frequency of BV13S1-positive CD4 cells. Immunogenetics 2000;51:296-305 47. Warmuth-Metz M, Becker G, Bendszus M, Solymosi L. Spinal canal stenosis in L-2- hydroxyglutaric aciduria. Arch Neurol 2000;57:1635-1637 48. Weishaupt A, Gold R, Hartung T, Gaupp S, Wendel A, Bruck W, Toyka KV. Role of TNF-alpha in high-dose antigen therapy in experimental autoimmune neuritis: inhibition of TNF-alpha by neutralizing antibodies reduces T-cell apoptosis and prevents liver necrosis. J Neuropathol Exp Neurol 2000;59:368-376 49. Weishaupt A, Jander S, Bruck W, Kuhlmann T, Stienekemeier M, Hartung T, Toyka KV, Stoll G, Gold R. Molecular mechanisms of high-dose antigen therapy in experimental autoimmune encephalomyelitis: rapid induction of Th1-type cytokines and inducible nitric oxide synthase. J Immunol 2000;165:7157-7163 50. Wohlleben G, Ibrahim SM, Schmidt J, Toyka KV, Hartung HP, Gold R. Regulation of Fas and FasL expression on rat Schwann cells. Glia 2000;30:373-381 51. Zielasek J, Martini R, Suter U, Toyka KV. Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve 2000;23:696-701

Übersichtsarbeiten, Buchartikel
1.
Bayas A, Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf 2000;22:149-159 Becker G, Müllges W. Spezielle Neurologische Diagnostik in der Intensivmedizin: Ultraschall. In: Burchardi H, Larsen R, Schuster HP, Suter PM: Intensivmedizin. Springer, 8.Auflage, 2000, 756-62 Berg D, Hoggenmuller U, Hofmann E, Fischer R, Kraus M, Scheurlen M, Becker G. The basal ganglia in haemochromatosis. Neuroradiology 2000;42:9-13 Flachenecker P, Toyka KV. Fruhdiagnostik der multiplen Sklerose. Versicherungsmedizin 2000;52:119-124 Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000;6:88-91 Jablonka S, Rossoll W, Schrank B, Sendtner M. The role of SMN in spinal muscular atrophy. J Neurol 2000;247 Suppl 1:I37-42 Müllges W, Franke D, Meixensberger J. Zur Differentialdiagnose des Alkoholentzugsanfalls: Subarachnoidalblutung. Intensivmed und Notfallmed 2000;37: 44-47

Source: http://www.neurologie.uk-wuerzburg.de/fileadmin/uk/neurologie/dokumente/publikationen2000bis2004.pdf